
Although genetic testing is still a relatively new development in drug treatment, but this field is rapidly expanding considering the…
Alembic has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from USFDA.
Currently, Asian nations are the largest API producers. The bulk of Active Pharmaceutical Ingredients companies are headquartered or formed in…
In the past 12 months, there was some fresh attention to new and innovative research in genomics, HIV, and the…
As the patient pool remains limited, the competition in the Oral Anti-Diabetic Drug (OAD) market has intensified. India has a…
A drug audit suggests that, in India, almost 80 per cent of all drugs are marketed as branded molecules and…
India has half a dozen major manufacturers of paracetamol led by players like Granules India and Sri Krishna Pharmaceuticals.
According to Bharat Biotech, the intranasal vaccine has several advantages because the nasal route has excellent potential for vaccination due…
On Thursday, Prime Minister Narendra Modi took stock of the COVID-19 situation in India and held a high-level virtual meeting.
The capsules have an estimated market size of US$ 244 million for twelve months ending Sep 2022 according to IQVIA.
The drug works by decreasing abnormal electrical activity in the brain.
Nifty Pharma index rises 2% as pharma, diagnostics stocks rally amid renewed Covid-19 outbreak fears. Dr Lal PathLabs, Vijaya Diagnostic…
According to the company, India has seen growth in pet ownership in the last decade which increased during the pandemic.
Earlier this year, Glenmark also launched Sitagliptin (Sitazit) and its FDCs, followed by Lobeglitazone (LOBG) and FDCs of Teneligliptin including…
He also serves as a board member for a number of US, European and regional Pharma, Biotech, Medical devices, Diagnostics,…
A recent survey by GlobalData has revealed that 36.4 of patients with diabetic neuropathic pain in 2021 were completely treatment…
The EU recommendation is based on a pooled analysis of trial data involving about 11,000 heart failure patients that showed…
According to the company, it is developing the proposed tocilizumab biosimilar as both subcutaneous and intravenous formulations.